Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • World View
  • Published:

Aducanumab: look before leaping

Nature Medicine volume 27, page 1499 (2021)Cite this article

Subjects

Lack of rigor in approving aducanumab for Alzheimer’s disease may lead to serious harm.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Departments of Neurology, Radiology and Neuroscience and Programs in Physical Therapy and Occupational Therapy, Washington University in St. Louis, St. Louis, MO, USA

    Joel S. Perlmutter

Authors
  1. Joel S. Perlmutter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel S. Perlmutter.

Ethics declarations

Competing interests

J.P. has received research funding from the US National Institutes of Health, the US Department of Defense, the Michael J Fox Foundation, the Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson disease research fund), the American Parkinson Disease Association Advanced Research Center at Washington University, the Greater St. Louis Chapter of the American Parkinson Disease Association, the Paula and Rodger Riney Fund, the Jo Oertli Fund, the Huntington Disease Society of America, the Murphy Fund and CHDI. J.P. has received honoraria from CHDI, the Huntington Disease Study Group, the Parkinson Study Group, Beth Israel Hospital (Harvard group), the University of Pennsylvania, Stanford University and Boston University. J.P. has provided medical legal consultation to Wood, Cooper and Peterson, LLC, and to Simmons and Simmons, LLP. J.P. was a member of the Peripheral and Central Nervous System Drugs Advisory Committee of the FDA but resigned on 7 June 2021, and participated in the advisory committee meeting of 6 November 2020.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perlmutter, J.S. Aducanumab: look before leaping. Nat Med 27, 1499 (2021). https://doi.org/10.1038/s41591-021-01477-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01477-5

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research